Successful Results in Clinical Trials Playing Important Role in Advanced Development of Therapeutic Drug Treatments for Various Diseases and Conditions

CORAL SPRINGS, Florida, September 21, 2015 /PRNewswire/ --

A series of encouraging clinical test trial results and the latest therapeutic advancements for drug therapies may be leading to the trend that the outlook for the biotech sector is still bright.  Recent trending biotech companies in focus are Q BioMed Inc (OTC: QBIO), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Can-Fite BioPharma Ltd. (NYSE: CANF), Inotek Pharmaceuticals Corp (NASDAQ: ITEK) and TapImmune, Inc. (OTC: TPIV).

Q BioMed Inc (OTC: QBIO), a biotechnology acceleration and development company is pleased to announce a Letter of Intent to in-license and ultimately acquire the assets of Mannin Research Inc.  Mannin Research Inc, is a biotechnology company leading the development of a new class of vascular therapeutics.  The drug development program at Mannin is led by Mannin's Chief Scientific Officer, Dr. Susan E. Quaggin, Chief of the Division of Nephrology and Director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago.  

Read the full QBIO Press Release at http://www.financialnewsmedia.com/profiles/qbio.html

Utilizing a proprietary research platform, only recently published (September 2014) in the Journal of Clinical Investigations, this technology is addressing the need for a new class of drugs to treat diseases such as Glaucoma and Cystic Kidney disease.  Our primary target indication is for a first-in-class therapeutic eye-drop for the treatment of Glaucoma in adults and children.  The global market for Glaucoma therapeutics is one of the largest segments of the $23 billion global ophthalmology market.  There are 60 million people worldwide suffering from Glaucoma.  It is projected that the total population suffering from Glaucoma will grow to 80 million by 2020 (W.H.O 2010). Our lead candidate, MAN-01, will address this market as a first-in-class drug that treats abnormal vessels within the eye, thereby treating Glaucoma at its root causes.  There have been no new class drugs developed for Glaucoma for 20 years, since Pfizer introduced Xalatan (latanaprost).

In other recent biotech/biopharma news and developments of interest:  Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, last week reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpoint demonstrating non-inferiority of Rhopressa™ compared to timolol, the most widely used comparator.

Can-Fite BioPharma Ltd. (NYSE: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced last week the U.S. Food and Drug Administration (FDA) has granted the Company's drug candidate CF102 Fast Track designation as a second line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer. CF102 had already received the FDA's Orphan Drug designation.  Can-Fite is currently conducting a Phase II study for this indication in the U.S., Europe and Israel. The randomized, double blind, placebo controlled study is expected to complete enrollment by the end of the first half of 2016 in 78 patients with Child-Pugh Class B cirrhosis who failed the only FDA approved drug on the market, Nexavar® (sorafenib). Patients are treated twice daily with 25 mg of oral CF102, which has been found to be the most efficacious dose in Can-Fite's earlier Phase I/II study resulting in the longest overall survival time, with excellent safety results.

Inotek Pharmaceuticals Corp (NASDAQ: ITEK)'s stock had its "overweight" rating restated by equities researchers at Piper Jaffray in a research report issued to clients and investors on Thursday, Analyst Ratings Network.com reports. They presently have a $29.00 price objective on the stock. Piper Jaffray's target price suggests a potential upside of 98.90% from the stock's previous close.  Read the full article here (http://www.wkrb13.com/markets/789929/inotek-pharmaceuticals-corp-stock-rating-reaffirmed-by-piper-jaffray-itek/)  Inotek Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma.

TapImmune, Inc. (OTC: TPIV) Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer. This grant, commencing September 15, 2015, covered the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer.  Award recipients are Keith L. Knutson. Ph.D., professor of Immunology at the Mayo Clinic Center for Immunology and Immune Therapies, and Edith A. Perez, M.D., deputy director at large for Mayo Clinic Cancer Center and the Serene M. and Frances C. Durling Professor of Medicine at Mayo Clinic College of Medicine, both at Mayo Clinic's Florida campus in Jacksonville.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook: facebook.com/financialnewsmedia and Twitter:  twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated four thousand nine hundred dollars for news coverage of the current press release issued by Q BioMed Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
U.S. Phone: +1-954-345-0611
URL: http://www.financialnewsmedia.com
Source:  FN Media Group

SOURCE FN Media Group LLC